Chemical Restraint Expert Witness

A chemical restraint is a medication used to control a resident's behavior for the staff's convenience or as discipline, rather than to treat a diagnosed medical condition. In nursing homes, it usually means an antipsychotic, benzodiazepine, or other sedating drug given to a resident with dementia who is agitated, loud, resistant to care, or simply hard to manage on a short-staffed shift. The resident becomes quieter and easier to manage, and often loses alertness, mobility, appetite, and the ability to swallow safely.

Chemical restraint cases turn on why the drug was given. The same antipsychotic can be appropriate for one resident and an unlawful restraint for another. An expert's job is to reconstruct the prescribing decision and show whether it was driven by a documented clinical need or by the facility's workload.

The legal standard

Federal regulations give nursing home residents the right to be free from chemical restraints imposed for discipline or convenience and not required to treat medical symptoms. They also prohibit unnecessary drugs, meaning drugs used in excessive doses, for excessive duration, without adequate monitoring, or without an adequate indication. CMS revised its interpretive guidance in 2025, consolidating oversight of unnecessary psychotropic use with the chemical restraint standard.

For psychotropic drugs specifically, federal rules require that:

• Residents not previously on a psychotropic aren't started on one unless it's necessary to treat a specific diagnosed condition
• Residents on psychotropics receive gradual dose reductions and behavioral interventions aimed at discontinuing the drug, unless clinically contraindicated
• As-needed (PRN) psychotropic orders are limited to 14 days unless the prescriber documents a rationale for extending them
• PRN antipsychotics can't be renewed without the prescriber evaluating the resident

Antipsychotics also carry an FDA boxed warning about increased mortality in elderly patients with dementia-related psychosis. That warning frames much of the testimony in these cases.

Recurring fact patterns

• No qualifying diagnosis. An antipsychotic started for "agitation" or "behaviors" with no documented psychiatric diagnosis supporting it.
• Diagnoses added to justify the drug. A schizophrenia or bipolar diagnosis appears in the record after admission with no psychiatric evaluation behind it. CMS has specifically audited this practice, because certain diagnoses exclude a resident from the facility's antipsychotic quality measure.
• Behavioral interventions skipped. Nothing documented about redirection, toileting, pain assessment, schedule changes, or other non-drug approaches before medication was used.
• Unmet needs treated as behavior. Pain, constipation, infection, hunger, or a need to toilet expressed as agitation and treated with sedation instead of evaluation.
• PRN orders used routinely. As-needed sedatives given on most shifts, often at times that line up with staffing shortages, care tasks, or night shift.
• No dose reductions. The same drug and dose continued for months or years with no attempt to taper.
• Consultant pharmacist ignored. Monthly pharmacy reviews flagged the drug, and the prescriber declined or never responded.
• No informed consent. The family or legal representative was never told about the drug, its purpose, or its risks.

The harm

Residents under chemical restraint suffer predictable complications:

• Falls and fractures from sedation, dizziness, and low blood pressure
• Aspiration pneumonia from impaired swallowing
• Dehydration and weight loss from reduced alertness and intake
• Pressure injuries from immobility
• Functional and cognitive decline
• Stroke and death, consistent with the boxed warning

Causation is often the most contested issue. The defense will argue that the decline reflected progression of dementia, not the medication. A strong causation opinion connects the timing of drug starts and dose increases to specific changes in the resident's condition.

Experts these cases draw

• Geriatric psychiatrist: whether a psychiatric diagnosis existed, whether the drug was indicated, and what appropriate treatment would have looked like.
• Geriatrician: medical causation, especially falls, aspiration, and decline.
• Consultant pharmacist: medication regimen review, dosing, interactions, and the pharmacy oversight process.
• Nursing expert: behavior monitoring, non-drug interventions, PRN administration, and documentation.
• Medical director expert: facility-level psychotropic oversight and response to pharmacist recommendations.

See also when your case needs two expert witnesses.

What the expert reviews

• Physician orders, including start dates, dose changes, and PRN orders
• Medication administration records, with PRN times and documented reasons
• Behavior monitoring logs and nursing notes describing behaviors
• Psychiatric evaluations and diagnosis history
• MDS assessments, especially mood and behavior sections
• Care plans for behaviors
• Consultant pharmacist reviews and prescriber responses
• Consent forms and family communication records
• Staffing sheets for the shifts when PRN doses were given
• Fall, weight, and hospitalization records over time

Mapping PRN administration times against staffing is often revealing. A pattern of doses on understaffed shifts, or right before care tasks, supports a convenience theory.

Qualifications to verify

Psychiatric experts should have geriatric experience treating patients with dementia in long-term care. General adult psychiatry is often not enough. Pharmacist experts should have worked as consultant pharmacists in nursing homes. Nursing experts should have long-term care dementia experience.

Defense themes

Defense counsel argue that the resident had genuine psychiatric symptoms, posed a danger to self or others, and that non-drug interventions were tried and failed. They also argue that decline was caused by underlying disease and that prescribing decisions were within the physician's judgment. A defense geriatric psychiatrist can be persuasive when the chart documents real psychosis or dangerous behavior.

Fee expectations

Psychiatrists and geriatricians bill at physician rates. Consultant pharmacists and nursing experts typically bill less. Review can be time-intensive because the analysis depends on reconstructing months of orders, PRN administration, and behavior documentation.

Frequently asked questions

Is every antipsychotic in a nursing home a chemical restraint?

No. An antipsychotic prescribed for a documented psychiatric condition, with monitoring and dose reduction attempts, can be entirely appropriate. The question is whether the drug treated a medical symptom or controlled behavior for convenience.

Can a pharmacist testify about causation?

Pharmacists can address pharmacology, dosing, and expected side effects. Medical causation for a specific injury usually needs a physician.

Why do diagnoses matter so much?

Federal rules require psychotropics to treat a specific diagnosed condition. A diagnosis added without an evaluation is often the clearest sign the drug was being used for behavior control.

What if the family consented?

Consent doesn't make an unnecessary drug necessary. It's one factor, and consent obtained without discussing risks or alternatives carries little weight.

Find a Chemical Restraint Expert Witness

Start an expert witness search